Search alternatives:
prevented decrease » prevented disease (Expand Search), prevalence decreased (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
prevented decrease » prevented disease (Expand Search), prevalence decreased (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
-
1
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
4
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
5
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
6
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
7
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
8
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
9
Table 2 -
Published 2024“…<div><p>Background</p><p>Evidence indicates that criminal behaviour in youth is linked with a range of negative physical, mental, and social health consequences. Despite a global decrease over the last 30 years, youth crime remains prevalent. …”
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
PGAM5 knockdown prevented rTsSPc from disrupting Caco-2 monolayer integrity.
Published 2025Subjects: -
20
Inhibition of PGAM5 and apoptosis prevented <i>T. spiralis</i> larval invasion of Caco-2 monolayer.
Published 2025Subjects: